Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial
British Journal of Dermatology · 2026
DOI: 10.1093/bjd/ljag052 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Cheng Zhou und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University People's Hospital, No. 11, Xizhimen South Street, Beijing, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Keymed Biosciences.
Abstract (Originalsprache)
Background
Moderate-to-severe atopic dermatitis (AD) imposes a significant burden on adolescents and their families, leading to a substantial reduction in quality of life. Treatment options remain limited. Stapokibart, a novel humanized monoclonal antibody that targets interleukin-4Rα, has been approved in China for the treatment of adults with moderate-to-severe AD.
Objectives
To evaluate the efficacy and safety of stapokibart in adolescents with moderate-to-severe AD.
Methods
In this randomized double-blind placebo-controlled phase III trial (NCT06277765), eligible patients were randomized (2 : 1) to stapokibart 300 mg (loading dose 600 mg) or placebo for 18 weeks. Patients with a baseline weight ≥ 60 kg received subcutaneous stapokibart or placebo every 2 weeks (Q2W), while those weighing 30 to < 60 kg received treatment every 3 weeks (Q3W). All patients were given moisturizers during the entire study period. Co-primary endpoints were the proportions of patients achieving a ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI 75) and an Investigator’s Global Assessment (IGA) score of clear or almost clear (IGA 0 or 1) with ≥ 2-point reduction from baseline (IGA response) at week 18. Safety was also assessed.
Results
Of the 180 enrolled patients, 120 received stapokibart (Q2W, n = 54; Q3W, n = 66) and 60 received placebo (Q2W, n = 26; Q3W, n = 34). In total, 178 (98.9%) patients completed the double-blind treatment. At week 18, higher proportions of patients treated with stapokibart than those treated with placebo achieved EASI 75 [73.9% (n = 88/119) vs. 43% (n = 26/60); difference: 30.5% (95% confidence interval 15.3–44.3; P < 0.001)] and an IGA response [57.1% (n = 68/119) vs. 25% (n = 15/60); difference: 31.8% (95% confidence interval 16.6–44.4; P < 0.001)]. The proportion of patients achieving ≥ 4-point reductions in weekly average of daily Peak Pruritus Numerical Rating Scale score was also significantly higher in the stapokibart group than in the placebo group [36.1% (n = 43/119) vs. 15% (n = 9/60); difference: 21.1% (95% confidence interval 7.4–32.4; P = 0.004)]. The incidence of adverse events was similar between the stapokibart (62.5%; n = 75/120) and placebo (62%; n = 37/60) groups. No conjunctivitis was seen.
Conclusions
Stapokibart has a high efficacy and favourable safety in adolescents with moderate-to-severe AD. An author video to accompany this article is available online.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Peking University People's Hospital, No. 11, Xizhimen South Street, Beijing, China.
ORCID-Profile: Zhu Wei, Hao Cheng, Xiao-Yong Man, Jianzhong Zhang
Förderung
- Keymed Biosciences
Zitieren
APA
Zhou, C., Zhao, Y., Zhu, G., Wu, L., Liu, Y., Tao, X., Zhao, H., Wei, Z., Lu, W., Li, W., Ding, Y., Zhu, X., Hu, G., Cheng, H., Xiao, R., Man, X. Y., Wang, Q., Li, S., Zeng, T., …, & Zhang, J. (2026). Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag052
Vancouver
Zhou C, Zhao Y, Zhu G, Wu L, Liu Y, Tao X, et al. Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag052
BibTeX
@article{Zhou2026,
author = {Zhou, Cheng and Zhao, Yan and Zhu, Guannan and Wu, Liming and Liu, Yi and Tao, Xiaohua and Zhao, Hengguang and Wei, Zhu and Lu, Wei and Li, Weiquan and Ding, Yangfeng and Zhu, Xiaohong and Hu, Guohong and Cheng, Hao and Xiao, Rong and Man, Xiao-Yong and Wang, Qi and Li, Shanshan and Zeng, Tongxiang and Wang, Lihua and Xu, Yufeng and Zhang, Libo and Liu, Wei and Zhao, Guoqing and Jia, Yingmin and Huang, Yanqiu and Chen, Bo and Zhang, Jianzhong},
title = {Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial},
journal = {British Journal of Dermatology},
year = {2026},
doi = {10.1093/bjd/ljag052}
}
EUVIMED